Clinical TrialA pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
Under a Creative Commons license
open access
Graphical abstract
Keywords
chronic kidney disease
dapagliflozin
DAPA-CKD
IgA nephropathy
randomized controlled clinical trial
sodium-glucose cotransporter inhibitor
Cited by (0)
see commentary on page 24
© 2021 International Society of Nephrology. Published by Elsevier Inc.